Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

A Phase 1/2 Study of Azacitidine in Combination With Pembrolizumab and Epacadostat Advanced Solid Tumors including Lung and Colorectal Cancer

ABSTRACT: Primary objectives: • Part 1: To evaluate the safety and tolerability and to determine the maximum tolerated dose (MTD; or the maximum tested dose) of the combination in subjects with advanced or metastatic solid tumors. • Part 2: To evaluate the efficacy of the combination in subjects with previously treated Stage IIIB or Stage IV non–small cell lung cancer (NSCLC), Stage IV microsatellite stable (MSS) colorectal cancer (CRC), and other select solid tumors by assessing the objective response rate (ORR) per RECIST v1.1 at the MTD or maximum tested dose. Primary endpoints: • Part 1: Safety and tolerability will be assessed by monitoring the frequency, duration, and severity of adverse events (AEs); through physical examinations; by evaluating changes in vital signs and electrocardiograms (ECGs); and through clinical laboratory blood and urine sample evaluations. • Part 2: Objective response rate, defined as the percentage of subjects having a complete response (CR) or partial response (PR), will be determined by investigator assessment of radiographic disease as per RECIST v1.1.

DISEASE(S): Metastatic Colorectal Cancer,Colorectal Cancer Stage Iv,Non-small Cell Lung Cancer Stage Iv,Advanced Cancer,Non-small Cell Lung Cancer Stage Iiib,Subjects With Advanced Solid Tumors And Previously Treated Stage Iiib Or Stage Iv Non–small Cell Lung Cancer And Stage Iv Microsatellite Stable Colorectal Cancer

PROVIDER: 2536320 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

ACCESS DATA

Json Xml

Similar Datasets

Biopsies from advanced melanoma before and/or after treatment with nivolumab

Project description:Expression profiling of tumor samples obtained during CA209-038 (ClinicalTrials.gov Identifier: NCT01621490). The purpose of this study is to evaluate pharmacodynamic changes of nivolumab and nivolumab in combination with ipilimumab treatment on the biomarkers measured in the peripheral blood and tumor tissues of subjects with advanced melanoma (unresectable or advanced). Samples are rumor core needle biopsies obtained at trial enrolment (i.e. Screen) and/or at Cycle 1 Day 29 (i.e.Week 4) from Subjects With Advanced Melanoma (Unresectable or Metastatic) treated with nivolumab (BMS-936558,MDX-1106) 3 mg/kg solution intravenously every 2 weeks on Bristol-Myers Squibb clinical trial protocol CA209-038 Part 1 . Cohort 2 patients have progressed on anti-CTLA4 (ipilimumab) monoclonal antibody therapy. Values are from an interim lock of the trial data in July 2014. Best overall response (BOR) was defined using RECIST 1.1 criteria: tumor assessments between date of first dose and the date of first objectively documented progression, or the date of non-missing subsequent anti-cancer therapy (whichever occurs first) were used to derive BOR. MPCT is Maximum reduction in tumor size (index lesions only) up to first progression, and is the value typically shown on a waterfall plot.

2022-01-01 | E-MTAB-4030 | biostudies-arrayexpress

miRNA expression profiles of erythroid cells following hydroxyurea treatment for sickle cell anemia

Project description:We hypothesized that miRNA regulation may be invloved in hydroxyurea-mediated fetal hemoglobin induction. Microarray analysis was utilized as an initial screening tool to determine differential miRNA expression in CD71+ erythroid cells comparing cells from control individuals without sickle cell anemia to patients with sickle cell anemia prior to treatment with hydroxyurea and patients receiving the maximum tolerated dose (MTD) of hydroxurea. CD71+ cells were isolated from whole blood of control individuals (n=2), pediatric patients without hydroxyurea treatment (n=3) and pediatric patients at hydroxyurea MTD (n=3). All 8 samples were analyzed for miRNA expression.

2011-11-21 | E-GEOD-32035 | biostudies-arrayexpress

miRNA expression profiles of erythroid cells following hydroxyurea treatment for sickle cell anemia

2011-11-21 | GSE32035 | GEO

Examination of microRNA expression in pre- and post-treatment plasma samples of 3 patients

Project description:Drug resistance often tempers the clinical benefit of chemotherapy in human malignant tumors. The potential chemosensitization of low-dose decitabine has been evident both preclinically and in previous phase I trials. Emerging data showed that miRNAs play an important role as a prognostic factor for cancer survival. Given that the biopsy tumor tissue was often not available, especially for patients with relapsed or refractory cancer, plasma RNA provided a valuable source for biomarker development. In order to establish predictive biomarker signature for the clinical efficacy of the decitabine-primed chemotherapy, we evaluated the expression of plasma miRNAs via high throughput microRNA sequencing. We performed miRNA-seq on a training set of 2 partial response (PR) patients and 1 progressive disease (PD) patients, and revealed preliminary data that plasma miRNA expression signature may serve as putative predictive markers of the low-dose decitabine primed chemotherapy. The clinical responses were assessed in a blinded manner according to the Response Evaluation Criteria in Solid Tumors (RECIST) v1.1.

2016-12-15 | GSE91089 | GEO

A study to evaluate CM24 in combination with nivolumab in adults with solid tumours

Project description:Primary objectives: Part A• To assess the safety, tolerability and the maximum tolerated dose (MTD) of CM24 in combination with 480mg nivolumab in adults with selected recurrent or metastatic solid tumors.• Determine the recommended Phase 2 dose level (RP2D) of CM24 in combination with nivolumab Part BTo assess the efficacy of the recommended phase 2 dose (RP2D) of CM24 in combination with nivolumab in adults with immune-checkpoint refractory recurrent or metastatic NSCLC based on Objective Response Rate (ORR). Part CTo assess the efficacy of CM24 in combination with nivolumab and nabpaclitaxel in adults with metastatic pancreatic cancer based on Objective Response Rate. Primary endpoints: Part ASafety and tolerability Parts B and CObjective response rate (ORR) based on RECIST Version 1.1

| 2540836 | ecrin-mdr-crc

A Study of Novel Oncology Therapies in Combination with FOLFOX and Bevacizumab in Metastatic Microsatellite-Stable Colorectal Cancer

Project description:Primary objectives: Part 1: To evaluate the safety and tolerability profile of FOLFOX + bevacizumab + novel oncology therapy combinations Part 2: To compare the efficacy of FOLFOX + bevacizumab + novel oncology therapy combinations versus FOLFOX + bevacizumab Primary endpoints: Part 1: Incidence of adverse events (AEs), serious adverse events (SAEs), dose-limiting toxicities (DLTs), laboratory findings, and vital signs Part 2: Objective response (OR) per RECIST v1.1

| 2538990 | ecrin-mdr-crc

RASTRIC-trial: investigating the safety and efficacy of a new three drug treatment combination for RAS-mutated metastastic colorectal cancer.

Project description:Primary objectives: Phase I The main objective of the phase I part is to determine safety and the recommended phase II dose (RP2D) of the triple combination. Phase II The main objective of the phase II part is to determine efficacy of the triplet combination defined by objective response rate according to RECIST 1.1. Primary endpoints: For the phase I dose-escalation trial: The primary endpoint is the incidence of DLTs leading to a RP2D. The RP2D of the triplet will be the MTD which is defined as the dose level that can be given to 6 subjects such that not more than 1 subject experiences a DLT. For the phase II trial: The primary endpoint is best overall response (OR), defined as complete response (CR) + partial response (PR) within 6 months, based on RECIST 1.1.

| 2539846 | ecrin-mdr-crc

NCIC CTG MA.22 phase I/II trial of epirubicin and docetaxel in locally advanced breast cancer on 2-weekly or 3-weekly schedules

Project description:This phase I/II neoadjuvant trial determined maximally-tolerated doses (MTD), dose-limiting toxicities (DLT), response-to-therapy, and explored the role of new response biomarkers. The combination regimens were delivered with acceptable toxicity, good clinical response, inducing changes in tumor RNA content and integrity. Pre-treatment gene expressions impacted clinical response, including several near 17q12, which with ERBB2, may better identify chemoresponsiveness.

2015-11-11 | GSE66999 | GEO

Pembrolizumab Combined With Itacitinib (INCB039110) and/or Pembrolizumab Combined With INCB050465 in Advanced Solid Tumors

Project description:This is an open-label, multicenter, Phase 1b platform study in subjects with advanced or metastatic solid tumors (Part 1a) and subjects with selected solid tumors (Part 1b and Part 2). Two treatment groups (Group A and Group B) will be evaluated Part 1a utilizes a 3+3 design to evaluate pembrolizumab and INCB combinations in advanced solid tumors. Group A will evaluate a JAK inhibitor with JAK1 selectivity itacitinib (INCB039110) in combination with pembrolizumab (MK-3475) and Group B will evaluate a PI3K-delta inhibitor (INCB050465) in combination with pembrolizumab to determine the maximum tolerated dose (MTD) or PAD and recommend a dose for the Part 1b safety expansion with each combination. Once the recommended dose has been identified in Part 1a, subjects with select solid tumor types will be enrolled into safety expansion cohorts based upon prior treatment history with a PD-1 pathway-targeted agent (Part 1b) for each combination. Part 2 utilizes a Simon 2-Stage design to evaluate INCB050465 in combination with pembrolizumab in patients with small cell lung cancer (SCLC) and a 1 stage design to evaluate the combination in patients with non-small cell lung cancer (NSCLC) and urothelial cancer (UC).

| 2205534 | ecrin-mdr-crc

A Phase 1/2, Open-label, Multicenter Study to Investigate the Safety, Pharmacokinetics, and Efficacy of Fadraciclib (CYC065), an Oral CDK2/9 Inhibitor, in Subjects With Advanced Solid Tumors and Lymphoma

Project description:Primary objectives: Phase 1: To determine the maximum-tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D) of fadraciclib when administered orally twice daily (BID) in 28-day cycles in adult subjects with advanced solid tumors and lymphoma Phase 2: To evaluate preliminary efficacy of fadraciclib as measured by overall response rate (ORR) in subjects with locally advanced, recurrent, or metastatic, histologically confirmed advanced solid tumors or lymphoma who have failed all standard therapies or for whom standard therapy does not exist Primary endpoints: Phase 1: The incidence rate of dose-limiting toxicities (first cycle only) at each dose level Phase 2:ORR according to Response Evaluation Criteria in Solid Tumors: RECIST guidelines (Lugano Criteria for lymphoma, mSWAT for CTCL) for each tumor type

| 2541477 | ecrin-mdr-crc

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data